en Health Services, Quality of Life and Outcomes Review Article <div style="text-align: justify;"><span style="font-size:16px;"><span style="font-family:Times New Roman;"><strong>Int</strong><strong>r</strong><strong>oduction</strong><strong>: </strong>A systematic review and meta-analysis was conducted to assess the efficacy and safety of iodine-125 implantation combined with gemcitabine in the treatment of advanced pancreatic cancer.<br> <strong>Methods</strong><strong>: &nbsp;</strong>PubMed, &nbsp;Chinese &nbsp;National &nbsp;Knowledge &nbsp;Infrastructure &nbsp;database &nbsp;(CNKI), Cochrane Library, Embase, and Wanfang database through Oct 2020 were searched<br> for randomized controlled trials (RCTs) and retrospective studies assessing the efficacy<br> and &nbsp;safety &nbsp;of &nbsp;iodine-125 &nbsp;implantation &nbsp;combined &nbsp;with &nbsp;gemcitabine &nbsp;in &nbsp;the &nbsp;treatment &nbsp;of advanced &nbsp;pancreatic &nbsp;cancer. &nbsp;The &nbsp;main &nbsp;outcome &nbsp;measures &nbsp;included &nbsp;the &nbsp;overall &nbsp;remission [complete &nbsp;response &nbsp;(CR)+partial &nbsp;response &nbsp;(PR)] &nbsp;rate, &nbsp;overall &nbsp;survival &nbsp;(OS), &nbsp;hypofunction of the liver, clinical benefit response (CBR) rate, survival rate, and adverse events.<br> <strong>Results</strong><strong>:&nbsp; &nbsp;</strong>Totally,&nbsp; &nbsp;19&nbsp; &nbsp;studies&nbsp; &nbsp;involving&nbsp; &nbsp;1496&nbsp; &nbsp;patients&nbsp; &nbsp;were&nbsp; &nbsp;included&nbsp; &nbsp;in&nbsp; &nbsp;the&nbsp; &nbsp;current systematic review and meta-analysis. The pooled results showed that efficacy and safety of &nbsp;patients &nbsp;treated &nbsp;with &nbsp;Iodine-125 &nbsp;combined &nbsp;with &nbsp;gemcitabine &nbsp;were &nbsp;superior &nbsp;to &nbsp;those undergoing &nbsp;gemcitabine &nbsp;alone: &nbsp;overall &nbsp;remission &nbsp;(CR+PR) &nbsp;rate &nbsp;[odds &nbsp;ratio &nbsp;(OR)=3.10, 95% confidence interval (CI): 2.40, 4.00; P<0.00001], OS [hazard ratio (HR)=0.56, 95% CI: 0.47, 0.68; P<0.00001], hypofunction of liver (OR=1.08, 95% CI: 0.67, 1.74;<br> P=0.75), CBR rate (OR=3.85, 95% CI: 2.83, 5.22; P<0.00001), survival rate of six months (OR=3.44 95% CI: 1.83, 6.46) and survival rate of 12 months (OR=2.67, 95% CI: 1.68, 4.26). And there was no statistical association in adverse events between the groups.<br> <strong>Conclusions</strong><strong>:&nbsp; &nbsp;</strong>The&nbsp; &nbsp;combination&nbsp; &nbsp;of&nbsp; &nbsp;iodine-125&nbsp; &nbsp;seed&nbsp; &nbsp;implantation&nbsp; &nbsp;and&nbsp; &nbsp;gemcitabine significantly prolonged the survival of patients with pancreatic cancer, compared with the gemcitabine alone, indicating a better prognosis.</span></span></div> Iodine-125, Pancreatic Neoplasms, Meta-Analysis, Gemcitabine 1 12 http://mcijournal.com/browse.php?a_code=A-10-500-2&slc_lang=en&sid=1 Jingxin Yan 583720460@qq.com 10031947532846003043 10031947532846003043 Yes Department of Interventional Therapy, Affiliated hospital of Qinghai University, Xining, China & Department of Postgraduate, Qinghai University, Xining, China Ting Li 1215946762@qq.com 10031947532846003044 10031947532846003044 No Department of Orthopedics, Sichuan People's Hospital, Chengdu, China & Department of Postgraduate, Chengdu Medical College, Chengdu, China Yaxuan Wang 1627608691@qq.com 10031947532846003045 10031947532846003045 No Department of Radiology, Chengdu Medical College, Chengdu, China Hao Zhu 675050874@qq.com 10031947532846003047 10031947532846003047 No Department of Ultrasound Medicine, People’s Hospital of Tibet Autonomous Region, Lhasa, China & Department of Postgraduate, Tibet University, Lhasa, China Ruihong Liu 949495231@qq,com 10031947532846003048 10031947532846003048 No Nanchong Central Hospital, North Sichuan Medical College, Nanchong, China Zhenwu Lei qhdxzhenwulei@foxmail.com 10031947532846003049 10031947532846003049 No Department of Interventional Therapy, Affiliated hospital of Qinghai University, Xining, China Yingxing Guo guoyingxing1962@qq.com 10031947532846003046 10031947532846003046 No Department of Interventional Therapy, Affiliated hospital of Qinghai University, Xining, China